Acromegaly Market Report 2026

Acromegaly Market Overview

• Acromegaly market size has reached to $2.56 billion in 2025 • Expected to grow to $5.84 billion in 2030 at a compound annual growth rate (CAGR) of 18.1% • Growth Driver: Rising Hormonal Disease Prevalence Powers Growth In The Acromegaly Market • Market Trend: Innovative Solutions Drive Market Dominance In Acromegaly Treatment • North America was the largest region in 2025.

What Is Covered Under Acromegaly Market?

Acromegaly is a rare hormonal disorder that occurs when the pituitary gland, a small gland located at the base of the brain, produces excessive growth hormone. This excess growth hormone leads to the enlargement and thickening of bones and tissues in various body parts, particularly the hands, feet and face. The main types of acromegaly are ectopic acromegaly and acromegaly due to growth hormone. Ectopic acromegaly is a rare medical condition characterized by excessive growth hormone (GH) production from a source outside the pituitary gland. The various types of diagnosis are involved, such as GH and IGF-I measurement, growth hormone suppression tests, imaging and others. These can be administered through several routes, including oral, parenteral and others. The types of treatments are available, including medication, somatostatin analogues, dopamine agonists, growth hormone antagonists, surgery, radiation and others, which are used by several end users, including hospitals, specialty clinics, homecare and others.

What Is The Acromegaly Market Growth Forecast?

The acromegaly market size is expected to see rapid growth in the next few years. It will grow to $5.84 billion in 2030 at a compound annual growth rate (CAGR) of 18.1%. The growth in the forecast period can be attributed to development of advanced somatostatin analogues, expansion of parenteral treatment options, rising adoption of precision medicine approaches, increasing homecare and outpatient treatment models, integration of digital health and remote monitoring solutions. Major trends in the forecast period include increasing adoption of growth hormone measurement and igf-i testing, rising use of somatostatin analogues and dopamine agonists, expansion of minimally invasive surgery and radiation therapy, growing focus on personalized treatment plans for patients, enhanced awareness and early diagnosis programs.

Global Acromegaly Market Segmentation

1) By Type: Ectopic Acromegaly, Acromegaly Due To Growth Hormone 2) By Diagnosis: GH And IGF-I Measurement, Growth Hormone Suppression Test, Imaging, Other Diagnosis 3) By Route Of Administration: Oral, Parental, Other Routes Of Administration 4) By Treatment: Medication, Somatostatin analogues, Dopamine Agonists, Growth Hormone Antagonist, Surgery, Radiation, Other Treatments 5) By End Users: Hospitals, Specialty Clinics, Other End Users Subsegments: 1) By Ectopic Acromegaly: Tumor-Induced Ectopic Acromegaly, Non-Tumor-Induced Ectopic Acromegaly 2) By Acromegaly Due To Growth Hormone: Primary Growth Hormone Excess, Secondary Growth Hormone Excess

What Is The Driver Of The Acromegaly Market?

The growing number of hormonal diseases such as diabetes is expected to propel the growth of the acromegaly market going forward. Hormonal diseases, also known as endocrine disorders, are medical conditions that result from dysfunction in the endocrine system. Diabetes is one of the most prevalent and significant hormonal diseases. Acromegaly and other endocrine diseases can result from the overproduction of some hormones, such as growth hormone or cortisol. Additionally, due to the impact of high amounts of growth hormone on insulin synthesis, about 50% of people with acromegaly may develop insulin resistance or type 2 diabetes mellitus. For instance, in March 2024, according to the Office for Health Improvement and Disparities, a UK-based government department, between March 2022 and March 2023, the percentage of individuals with type 1 diabetes receiving all eight recommended care processes increased by 22%, and for type 2 diabetes, it increased by 21%, while the percentage achieving target HbA1c levels rose to 37.9%, the highest value ever reported by the National Diabetes Audit (NDA). Therefore, the growing number of hormonal diseases is driving the growth of the acromegaly industry.

Key Players In The Global Acromegaly Market

Major companies operating in the acromegaly market are Pfizer Inc., Johnson & Johnson Private Limited, Merck & Co Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH., Amgen Inc., Allergan Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Ipsen Pharma S.A., Hikma Pharmaceuticals PLC, Lupin Ltd., Recordati S.p.A., Ionis Pharmaceuticals Inc., Amryt Pharma plc , Strongbridge Biopharma plc, Aquestive Therapeutics Inc., Peptron Inc., Crinetics Pharmaceuticals, Chiasma Inc.

Global Acromegaly Market Trends and Insights

Major companies operating in the acromegaly market are focused on developing innovative products and solutions, such as generic lanreotide, to enhance treatment options and improve patient outcomes. Generic lanreotide refers to a non-branded formulation of the medication used to treat acromegaly and certain neuroendocrine tumors. It acts as a somatostatin analogue, reducing growth hormone secretion and improving patient accessibility to effective treatment options. For instance, in October 2024, Teva Pharmaceutical Industries Ltd., an Israel-based pharmaceutical company focused on generic drugs, launched the first and only generic version of Sandostatin LAR Depot in the United States. The injectable suspension, octreotide acetate, is indicated for treating acromegaly and severe diarrhea associated with carcinoid syndrome. This introduction enhances access to crucial therapy for patients requiring these treatments.

What Are Latest Mergers And Acquisitions In The Acromegaly Market?

In July 2024, AstraZeneca plc, a UK-based multinational pharmaceutical and biotechnology company, acquired Amolyt Pharma for $1.05 billion. The acquisition strengthens AstraZeneca's pipeline in rare disease treatments, especially endocrine and metabolic disorders, as Amolyt's innovative therapies align with the company’s commitment to advancing patient care and addressing unmet medical needs. Amolyt Pharma is a France-based clinical-stage biopharmaceutical company that develops treatments for rare endocrine diseases, including eneboparatide for hypoparathyroidism and AZP-3813, a peptide antagonist for acromegaly.

Regional Outlook

North America was the largest region in the acromegaly market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Acromegaly Market?

The acromegaly market consists of revenues earned by entities by providing hormone replacement therapy, pituitary radiotherapy and lifestyle modifications. The market value includes the value of related goods sold by the service provider or included within the service offering. The acromegaly market also includes sales of octreotide, lanreotide and somavert. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Acromegaly Market Report 2026?

The acromegaly market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the acromegaly industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.